Tifacogin for CAP?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chiron is planning a Phase III trial of tifacogin for severe community-acquired pneumonia. Development for severe sepsis, in collaboration with Pharmacia, was suspended in November 2001 because the tissue factor pathway inhibitor failed to meet its primary endpoint of 28-day all cause mortality. Chiron has acquired all of Pfizer's interest in tifacogin; Pfizer will receive royalties on tifacogin sale
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.